Hepatitis C Biopump Trials Get Green Light
Share
Follow Us
Timing Couldn’t Be Better for First Human Clinical Trials of Biopump Technology for Hepatitis C
* Reuters is not responsible for the content in this press release.
Thu Aug 30, 2012 6:20am EDT
In a leap forward for viral medicine no less important than the first studies in HIV decades ago, Medgenics, Inc. (AMEX:MDGN) is set to begin two human clinical trials for its INFRADURE Biopump to test a continuous release of naturally-produced interferon alpha for hepatitis C.
This may, perhaps someday pit it against widely-used PEG-interferon/ribavirin with its host of highly unpleasant side effects such as debilitating flu-like symptoms, depression, bloody diarrhea, and a potential for developing Type 2 diabetes.
Continue reading this entire article:
http://www.reuters.com/article/2012/08/30/idUS105781+30-Aug-2012+HUG20120830
